Law360, New York (October 10, 2004, 12:00 AM ET) -- The authors of the Hatch-Waxman Act signaled their concern about the growing popularity of so-called “authorized generics” agreements at an industry conference last week, warning that the issue is serious enough to warrant congressional examination.
During a two-day Drug & Device Dialogue conference called “Following On Hatch-Waxman: Credentials for Success,” Sen. Orrin Hatch (R-Utah) and Rep. Henry Waxman (D-Calif.) hinted the impact of authorized generics on competition in the pharmaceutical sector is undermining the principles of the Hatch-Waxman Act.
"I think that's certainly an area that...
Hatch, Waxman Signal Concern About "Authorized Generics"
To view the full article, take a free trial now.
